转移性黑色素瘤-话题@MedSci

#转移性黑色素瘤#

35篇内容 | 2345人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361591, encodeId=acde1361591dd, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=102, createdTime=2022-07-10, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361590, encodeId=ba5913615905f, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=111, createdTime=2022-03-21, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361589, encodeId=94b513615894d, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=124, createdTime=2022-03-16, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361588, encodeId=77f91361588dd, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=90, createdTime=2022-02-17, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361587, encodeId=eee7136158eb2, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=78, createdTime=2022-01-17, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361586, encodeId=01db13615860c, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析, objectType=article, longId=215870, objectId=7c302158e0f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c302158e0f8, replyNumber=0, likeNumber=119, createdTime=2021-08-18, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c302158e0f8, moduleTitle=Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c302158e0f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361585, encodeId=f1451361585b3, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=137, createdTime=2021-07-24, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361584, encodeId=02ad1361584cc, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, objectType=article, longId=214405, objectId=fc05214405fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc05214405fd, replyNumber=0, likeNumber=82, createdTime=2021-07-20, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc05214405fd, moduleTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc05214405fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361583, encodeId=fd4c136158348, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=71, createdTime=2021-07-17, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361582, encodeId=f9e613615823c, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, objectType=article, longId=213744, objectId=3257213e448e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3257213e448e, replyNumber=0, likeNumber=72, createdTime=2021-07-06, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3257213e448e, moduleTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3257213e448e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361581, encodeId=2196136158109, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物, objectType=article, longId=213534, objectId=bbe3213534a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbe3213534a2, replyNumber=0, likeNumber=0, createdTime=2021-07-01, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbe3213534a2, moduleTitle=Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbe3213534a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361580, encodeId=6f771361580bb, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=73, createdTime=2021-06-28, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361579, encodeId=0b0413615e94c, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性, objectType=article, longId=211237, objectId=ce0a21123ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce0a21123ee7, replyNumber=0, likeNumber=98, createdTime=2021-05-15, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce0a21123ee7, moduleTitle=JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce0a21123ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361578, encodeId=471e13615e82a, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Br J Cancer：免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关, objectType=article, longId=208869, objectId=3c442088690f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c442088690f, replyNumber=0, likeNumber=97, createdTime=2021-03-24, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c442088690f, moduleTitle=Br J Cancer：免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c442088690f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361577, encodeId=cd3313615e73e, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效, objectType=article, longId=177709, objectId=11801e770906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11801e770906, replyNumber=0, likeNumber=108, createdTime=2019-08-17, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11801e770906, moduleTitle=NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11801e770906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361576, encodeId=cd7513615e635, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=溶瘤病毒有效治疗40%无法进行手术的转移性黑色素瘤, objectType=article, longId=159145, objectId=8d4c15914541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d4c15914541, replyNumber=0, likeNumber=90, createdTime=2019-01-30, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d4c15914541, moduleTitle=溶瘤病毒有效治疗40%无法进行手术的转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d4c15914541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361575, encodeId=4b6913615e52e, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=CLIN CANCER RES：Treg磷酸化STAT3增加以及抑制功能降低与转移性黑色素瘤患者PD-1阻断治疗获益有关, objectType=article, longId=156393, objectId=f98b15639322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f98b15639322, replyNumber=0, likeNumber=107, createdTime=2018-12-23, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f98b15639322, moduleTitle=CLIN CANCER RES：Treg磷酸化STAT3增加以及抑制功能降低与转移性黑色素瘤患者PD-1阻断治疗获益有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f98b15639322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361574, encodeId=5cdc13615e484, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=EJC：转移性黑色素瘤患者中血浆总游离DNA作为肿瘤负担和预后评价的替代性标志物, objectType=article, longId=154092, objectId=22b9154092a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22b9154092a1, replyNumber=0, likeNumber=106, createdTime=2018-11-23, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22b9154092a1, moduleTitle=EJC：转移性黑色素瘤患者中血浆总游离DNA作为肿瘤负担和预后评价的替代性标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22b9154092a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361573, encodeId=23a213615e300, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, objectType=article, longId=149597, objectId=26f714959eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f714959eaf, replyNumber=0, likeNumber=82, createdTime=2018-09-27, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f714959eaf, moduleTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f714959eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, objectTitle=CLIN CANCER RES：抗CTLA4治疗对过继TIL疗法治疗转移性黑色素瘤患者的影响, objectType=article, longId=149295, objectId=4fc11492954f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fc11492954f, replyNumber=0, likeNumber=96, createdTime=2018-09-23, rootId=0, userName=lixiao3326, userId=d39f177, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fc11492954f, moduleTitle=CLIN CANCER RES：抗CTLA4治疗对过继TIL疗法治疗转移性黑色素瘤患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fc11492954f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性黑色素瘤

2020-05-29

lixiao3326

#转移性黑色素瘤#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-07-10

lixiao3326

#转移性黑色素瘤#

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2022-03-21

lixiao3326

#转移性黑色素瘤#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-03-16

lixiao3326

#转移性黑色素瘤#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2022-02-17

lixiao3326

#转移性黑色素瘤#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-01-17

lixiao3326

#转移性黑色素瘤#

Br J Cancer：血浆ctDNA检测转移性黑色素瘤患者的临床进展分析

2021-08-18

lixiao3326

#转移性黑色素瘤#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-07-24

lixiao3326

#转移性黑色素瘤#

Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效

2021-07-20

lixiao3326

#转移性黑色素瘤#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2021-07-17

lixiao3326

#转移性黑色素瘤#

罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗

2021-07-06

lixiao3326

#转移性黑色素瘤#

Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物

2021-07-01

lixiao3326

#转移性黑色素瘤#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-06-28

lixiao3326

#转移性黑色素瘤#

JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性

2021-05-15

lixiao3326

#转移性黑色素瘤#

Br J Cancer：免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关

2021-03-24

lixiao3326

#转移性黑色素瘤#

NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效

2019-08-17

lixiao3326

#转移性黑色素瘤#

溶瘤病毒有效治疗40%无法进行手术的转移性黑色素瘤

2019-01-30

lixiao3326

#转移性黑色素瘤#

CLIN CANCER RES：Treg磷酸化STAT3增加以及抑制功能降低与转移性黑色素瘤患者PD-1阻断治疗获益有关

2018-12-23

lixiao3326

#转移性黑色素瘤#

EJC：转移性黑色素瘤患者中血浆总游离DNA作为肿瘤负担和预后评价的替代性标志物

2018-11-23

lixiao3326

#转移性黑色素瘤#

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

2018-09-27

lixiao3326

#转移性黑色素瘤#

CLIN CANCER RES：抗CTLA4治疗对过继TIL疗法治疗转移性黑色素瘤患者的影响

2018-09-23

科室
- - 订阅+
  - 更多科室
工具
服务